1. Show article details.

    BRIEF-Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements In Its Broad Genome Editing Capabilities At The 2021 European Society Of Gene & Cell Therapy Annual Congress

    Reuters – 7:36 AM ET 10/20/2021

    Intellia Therapeutics Inc (NTLA): * INTELLIA THERAPEUTICS PRESENTS PRECLINICAL DATA DEMONSTRATING ADVANCEMENTS IN ITS BROAD GENOME EDITING CAPABILITIES AT THE 2021 EUROPEAN SOCIETY OF GENE & CELL THERAPY ANNUAL CONGRESS Source text for Eikon: Further company coverage:

  2. Show article details.

    Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress

    GlobeNewswire – 7:30 AM ET 10/20/2021

    CAMBRIDGE, Mass., Oct. 20, 2021 -- Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced new data supporting novel capabilities of its CRISPR/Cas9 genome editing platform, which the Company plans to leverage for the development of future therapeutic candidates.

  3. Show article details.

    BRIEF-Intellia Therapeutics And Sparingvision Announce Strategic Collaboration To Develop Novel Ocular Therapies Using Crispr/Cas9 Technology

    Reuters – 7:13 AM ET 10/13/2021

    Intellia Therapeutics Inc (NTLA): * INTELLIA THERAPEUTICS AND SPARINGVISION ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP NOVEL OCULAR THERAPIES USING CRISPR/CAS9 TECHNOLOGY. * INTELLIA - WILL GRANT SPARINGVISION EXCLUSIVE RIGHTS TO IN VIVO CRISPR/CAS9 TECHNOLOGY FOR DEVELOPMENT OF OCULAR THERAPIES DIRECTED TO THREE TARGETS.

  4. Show article details.

    Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

    GlobeNewswire – 7:01 AM ET 10/13/2021

    CAMBRIDGE, Mass. and PARIS, Oct. 13, 2021 -- Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, and SparingVision, a genomic medicine company developing vision saving treatments for ocular diseases, today announced a strategic collaboration to develop novel genomic medici...

  5. Show article details.

    Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 2021 European Society of Gene & Cell Therapy Annual Congress

    GlobeNewswire – 7:30 AM ET 10/12/2021

    CAMBRIDGE, Mass., Oct. 12, 2021 -- Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the presentation of new data at the 29th Annual Congress of the European Society of Gene & Cell Therapy meeting, taking place virtually from October 19-21, 2021.

  6. Show article details.

    BRIEF-Intellia Therapeutics Inc Receives Authorization To Initiate Phase 1/2 Clinical Trial Of NTLA-2002

    Reuters – 7:36 AM ET 10/06/2021

    Intellia Therapeutics Inc (NTLA): * INTELLIA THERAPEUTICS RECEIVES AUTHORIZATION TO INITIATE PHASE 1/2 CLINICAL TRIAL OF NTLA-2002 FOR TREATMENT OF HEREDITARY ANGIOEDEMA. * Intellia Therapeutics Inc (NTLA) - ON TRACK TO INITIATE PATIENT ENROLLMENT BY YEAR-END.

  7. Show article details.

    Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

    GlobeNewswire – 7:30 AM ET 10/06/2021

    CAMBRIDGE, Mass., Oct. 06, 2021 -- Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the authorization of its Clinical Trial Application by the New Zealand Medicines and Medical Devices Safety Authority to initiate a Phase 1/2 study evaluating NTLA-200...

  8. Show article details.

    Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines Conference

    GlobeNewswire – 7:30 AM ET 09/27/2021

    Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at Chardan’s 5th Annual Genetic Medicines Conference on Monday, October 4, 2021 at 10:30 a.m. ET.

  9. Show article details.

    BRIEF-Intellia Reports U.S. FDA Acceptance Of IND Application For Its Candidate For Acute Myeloid Leukemia

    Reuters – 7:40 AM ET 09/16/2021

    Intellia Therapeutics Inc (NTLA): * INTELLIA THERAPEUTICS ANNOUNCES U.S. FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR NTLA-5001, ITS CRISPR/CAS9-ENGINEERED TCR-T CELL CANDIDATE FOR ACUTE MYELOID LEUKEMIA. * Intellia Therapeutics Inc (NTLA) - INITIATION OF PATIENT SCREENING IN PHASE 1/2A STUDY OF NTLA-5001 EXPECTED BY YEAR-END.

  10. Show article details.

    Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia

    GlobeNewswire – 7:30 AM ET 09/16/2021

    CAMBRIDGE, Mass., Sept. 16, 2021 -- Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced that the U.S. Food and Drug Administration has accepted the investigational new drug application for NTLA-5001, the company’s first wholly-owned ex vivo CRISPR genome ed...

  11. Show article details.

    Intellia Therapeutics to Present at September Healthcare Investor Conferences

    GlobeNewswire – 7:30 AM ET 08/31/2021

    Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the following virtual healthcare investor conferences in September: Thursday, September 9, 2021Wells Fargo Healthcare ConferenceTime: 10:40 am ET.

  12. Show article details.

    BRIEF-Intellia Therapeutics Announces Second Quarter 2021 Results

    Reuters – 8:13 AM ET 08/05/2021

    Intellia Therapeutics Inc (NTLA): * Intellia Therapeutics Inc (NTLA) - QTRLY LOSS PER SHARE $1.01 Source text for Eikon: Further company coverage:

  13. Show article details.

    Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress

    GlobeNewswire – 7:30 AM ET 08/05/2021

    CAMBRIDGE, Mass., Aug. 05, 2021 -- Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported financial results for the second quarter ended June 30, 2021, and recent operational highlights. “This quarter marked an exciting new chapter for Intellia.

  14. Show article details.

    Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates

    GlobeNewswire – 7:30 AM ET 07/29/2021

    Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its second quarter 2021 financial results and operational highlights in a conference call on August 5, 2021 at 8 a.m. E.T. To join the call: A replay of the call will be available through the Events and Prese...

  15. Show article details.

    Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock

    GlobeNewswire – 4:01 PM ET 07/02/2021

    Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today the closing of an underwritten public offering of 4,758,620 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 620,689 shares, at the p...

  16. Show article details.

    Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

    GlobeNewswire – 9:08 PM ET 06/29/2021

    Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today the pricing of an underwritten public offering of 4,137,931 shares of its common stock at a public offering price of $145.00 per share.

  17. Show article details.

    Intellia Therapeutics Announces Proposed Public Offering of Common Stock

    GlobeNewswire – 4:01 PM ET 06/28/2021

    Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that it has commenced an underwritten public offering of $400 million of shares of its common stock.

  18. Show article details.

    Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis

    GlobeNewswire – 11:15 AM ET 06/26/2021

    CAMBRIDGE, Mass. and TARRYTOWN, N.Y., June 26, 2021 -- Intellia Therapeutics, Inc. (NTLA) and Regeneron Pharmaceuticals, Inc. (REGN) today announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin amyloidosis.

  19. Show article details.

    Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary

    GlobeNewswire – 7:30 AM ET 06/24/2021

     Intellia Therapeutics (NTLA), Inc., a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary.

  20. Show article details.

    Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

    GlobeNewswire – 7:30 AM ET 06/04/2021

     Intellia Therapeutics (NTLA), Inc. today announced that a late-breaking abstract featuring interim Phase 1 clinical data from NTLA-2001, the Company’s lead CRISPR/Cas9 in vivo therapy in development as a single-dose, systemically administered treatment for transthyretin amyloidosis, has been selected for an oral presentation at the 2021 Peripheral Nerve Society Annual Meeting, taking place this mo...

Page:

Today's and Upcoming Events

  • Nov
    03

    NTLA to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    05

    NTLA announced Q2 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.